Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Form / Attachment / Pricing Sheet

This Excel file, "Aug 2026 PT Meeting Reporting.xlsx", contains detailed reporting data related to pharmaceutical utilization, specifically focusing on Oncological Agents (BRAF-MEK Inhibitors) and ADHD Agents (Stimulants). It appears to be a historical or projected usage report, likely intended for informational purposes or as a basis for future procurement decisions. The data covers the period of April 1, 2025, to March 31, 2026.

• Oncological Data: Includes dispensed quantities and 30-day equivalent prescriptions for specific oncological agents (e.g., BRAFTOVI, COTELLIC, MEKINIST, TAFINLAR, ZELBORAF) across Retail, MTF, and Mail Order service categories, broken down by quarter.
• ADHD Data: Details ADHD stimulant agents (e.g., ADDERALL, DEXTROAMPHETAMINE/AMPHETAMINE, METHYLPHENIDATE HCL) including package size, strength, dosage form, service category, manufacturer, and quantity dispensed over several quarters. It also includes National Drug Codes (NDCs), manufacturer information, strength, dosage form, and unit of measure for these agents.
• Location Data: Data is broken down by numerous locations, likely military bases or government facilities (e.g., KINGS BAY, KIRTLAND, LAKENHEATH, PENTAGON).
• Limitations: The title page notes limitations regarding data utility for research due to its dynamic nature and specific collection methods (MHS PDTS), including potential inaccuracies related to unpicked-up prescriptions, changes in dispensing, and inability to distinguish acute vs. chronic use or off-label uses.
• Pricing/Cost Data: Aggregated cost data (Sum of Total 30dEqRxs) for different fiscal quarters is provided for ADHD agents.

This document provides crucial historical data on the dispensing and utilization of specific oncological and ADHD medications within the Military Health System. Bidders responding to opportunities related to pharmacy operations, pharmaceutical support, or the supply and management of these specific oncology drugs and ADHD medications can use this data to understand historical usage patterns, quantities, distribution channels (Retail, MTF, Mail Order), and potentially inform pricing strategies and logistical planning. The noted data limitations are critical for accurate interpretation. The detailed product information (NDC codes, manufacturers, dosage forms) is valuable for understanding the market landscape and identifying potential suppliers.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) seeks pricing for pharmaceutical agents to be considered for placement on the Department of War (DoW) Uniform Formulary (UF). The DoW is establishing an integrated pharmacy benefits program for the Military Health System (MHS) as mandated by law. The Pharmacy and Therapeutics (P&T) Committee will evaluate agents based on clinical and cost-effectiveness to recommend their inclusion and classification (generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary) for cost-sharing purposes.

• Manufacturers are invited to submit offers that reduce DoW's cost for specific pharmaceutical agents.

• Quotes are required for two instruments: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP), and Uniform Formulary Additional Discount Program (UF ADP) for refunds on prescriptions filled by TRICARE retail network pharmacies.

• Quotes must include all relevant National Drug Codes (NDCs) for the pharmaceutical agent.

• Pricing must be TAA compliant.

• The contract type will be UF BPA and/or UF ADP agreements.

• Quotes must be valid for 180 days.

• The period of performance for resulting agreements will be until the drug class is reevaluated or the agreement is terminated.

• Key Deadlines:

  • Posting Date: May 7, 2026
  • Pre-Quotation Teleconference: May 13, 2026
  • Quotes Due: June 29, 2026
  • P&T Committee Meeting: August 5-6, 2026

• Submission Steps:

  1. Download Utilization Dataset and NDC Price List.
  2. Complete applicable pages and price appendices (Appendix 1 for all, Appendix 2 for BPA, Appendix 3 for ADP).
  3. Submit original signed quotes and NDC Price List to the RFQ Point of Contact.

• Evaluation Criteria:

  • The DoW P&T Committee will consider clinical effectiveness and relative cost effectiveness.
  • UF BPA and UF ADP quotes will be evaluated as part of the cost-effectiveness analysis.
  • Existing UF BPAs or UF ADPs will not be considered.

• Manufacturers must have an existing FSS contract or Interim Agreement.

• Quotes are for pharmaceutical agents identified for placement on the UF.

• A pre-quotation teleconference will be held on May 13, 2026.

• One-on-one appointments with the Industry Technical Liaison are available upon request.

• The document includes definitions and acronyms relevant to the solicitation.

• Appendix 1 provides a Manufacturer Quote Submission Checklist.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for ADHD Agents (Stimulants) as part of a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP). It is intended for the August 2026 DoW P&T Meeting.

• BPA Sheet: Lists Uniform Formulary (UF) and Non-Formulary (NF) scenarios for ADHD Stimulants. It indicates "NO QUOTE" for specific NDC numbers (e.g., 264AASTG1UF1M, 264AASTG1NF1M) under various conditions. It also notes that agents with RFQ not submitted or selected may be designated non-step preferred.
• ADP (non-FAMP Discount) Sheet: Details pricing scenarios for Tier 2 and Tier 3 ADHD Stimulants. It outlines calculations for "Total Calculated Refund Per FCP" based on non-FAMP prices and additional offered refunds. It specifies a quotes due date of 2026-06-29.
• General Notes: Both sheets mention that Prior Authorization (PA) may apply and that the P&T Committee may recommend preferential status or exclusion of certain agents. Manufacturers are reminded to submit the Quote Review Checklist and fully executed signature pages.

This document provides critical pricing and formulary status information for ADHD Stimulants. Bidders should note the "NO QUOTE" indications for specific scenarios on the BPA sheet and understand the refund calculation methodology on the ADP sheet. The quotes due date is June 29, 2026. The document also highlights potential formulary management strategies, such as preferential status or exclusion, which may impact product placement and reimbursement.

Form / Attachment / Pricing Sheet

This document contains pricing information for Oncological Agents, specifically BRAF-MEK Inhibitors, for the August 2026 P&T Meeting. It includes details for both a Blanket Purchase Agreement (BPA) Appendix and an Additional Discount Program (ADP) Appendix.

• BPA Appendix: Details Uniform Formulary (UF) and Non-Formulary (NF) scenarios for BRAF-MEK inhibitor combinations. It outlines requirements for "Before-Step Therapy" and "After-Step Therapy" and includes columns for NDC Number, Drug Name, Strength, Dosage Form, Package Size, and pricing per NDC/Unit. Notably, all entries indicate "NO QUOTE" for price.
• ADP Appendix: Focuses on non-FAMP (Federal Ceiling Price) discounts and refunds for TRICARE Retail. It outlines scenarios for Tier 2 and Tier 3 medications, including "Before-Step Therapy" and "After-Step Therapy." Columns include NDC Number, Drug Name, Strength, Dosage Form, Package Size, and various refund/pricing metrics (Non-FAMP Price, Additional Offered Refund, Current Annual FCP, Standard Refund, Total Calculated Retail Refund). All entries in this section are blank, indicating no specific pricing or refund data is provided.
• General Notes: Both sections mention that Prior Authorization (PA) may apply and that agents may be subject to special reimbursement methods. Step Therapy guidelines are detailed, including grandfathering for existing patients and requirements for new patients. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages. Quotes were due on 2026-06-29.

This document is crucial for manufacturers of BRAF-MEK inhibitor oncological agents. It outlines the pricing structure and formulary placement scenarios relevant to the August 2026 P&T Committee meeting. Bidders need to understand the step therapy requirements, potential prior authorizations, and the specific pricing and refund structures (or lack thereof, as indicated by "NO QUOTE" and blank fields) to determine their quoting strategy and eligibility for inclusion in the formulary. The due date for quotes was June 29, 2026.

Forms / Attachments / Pricing Sheets

This document, titled "Price Appendix FAQ," provides frequently asked questions and instructions for completing pricing spreadsheets related to a solicitation. It clarifies how to use the provided tables for both BPA (Business Partner Agreement) and ADP (Additional Drug Pricing) scenarios.

For BPA Scenarios:

• Bidders must read "Formulary Notes" for P&T committee decision-making context.
• Only yellow cells are editable; others are locked.
• Entering "Package Size" (column G) auto-populates remaining cells.
• A red highlight in "Price per NDC" (column F) indicates no quote is being submitted for that item.
• "Price per Unit" (column H) is auto-calculated.
• Bidders only need to fill out tables for their specific NDCs (up to 10 provided).
• For more than 10 NDCs, contact the RFQ POCs for an expanded spreadsheet.

For ADP Scenarios:

• Similar instructions regarding "Formulary Notes" and editable cells apply.
• Entering the first non-FAMP price (column F) and Current Annual Federal Ceiling Price (column H) auto-populates subsequent rows.
• A red highlight in "Additional offered refund" (column G) signifies no quote submission.
• Columns I and J (Total Calculated Refund) are auto-calculated, with formulas provided.
• Bidders should fill out tables for their specific NDCs (up to 10 provided).
• For more than 10 NDCs, contact the RFQ POCs for an expanded spreadsheet.

This document is crucial for bidders to accurately complete and submit pricing information as required by the solicitation. It provides step-by-step guidance on data entry, understanding auto-calculations, and interpreting specific indicators (like red highlighting) within the pricing spreadsheets. Bidders should pay close attention to these instructions to ensure their quotes are correctly formatted and submitted, and to understand how to request additional tables if needed.